4.2 Article

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

期刊

JOURNAL OF CHEMOTHERAPY
卷 20, 期 4, 页码 509-512

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1179/joc.2008.20.4.509

关键词

chemotherapy; metastatic disease; pancreatic cancer; docetaxel; salvage therapy

向作者/读者索取更多资源

Gemcitabine-based chemotherapy provides very limited disease control in the treatment of advanced pancreatic cancer. Approximately half of the patients failing upfront treatment present good performance status and are willing to undergo further treatment. Docetaxel activity against pancreatic cancer is reported both in the preclinical and clinical setting. Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS > 50, adequate organ function, were treated with weekly docetaxel at 30 mg/m(2) until progressive disease. Docetaxel dose intensity was 100% of the intended dose. No grade > 2 toxicity was observed. No objective response to treatment was obtained. Median progression-free survival was 1.5 months (range 1-3.5 months); median survival was 4.0 months (range 2.0-7.5). Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据